Line Planck Kongstad

Line Planck Kongstad

University of Southern Denmark, Odense, Syddanmark, Denmark
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2022 in Challenges
Verified
Journal Article
Open access
PDF file
HBHenriette Busk
Henriette Busk
USUlrik Sidenius
Ulrik Sidenius
LKLine Planck Kongstad
Line Planck Kongstad
SCSus sola Corazon
Sus sola Corazon
CPChristina Bjørk Petersen
Christina Bjørk Petersen
USUlrika Stigsdotter
Ulrika Stigsdotter
Introduction: Nature-based therapy (NBT) has shown positive effects on different health-related outcomes and is becoming a more frequent approach in various rehabilitative interventions. Economic evaluations are widely used to inform decision makers of cost-effective interventions. However, economic evaluations of NBT have not yet been reviewed. The aim of this review was to uncover existing types and characteristics of economic evaluations in the field of nature-based therapeutic interventions. Methods: In this scoping review available knowledge about the topic was mapped. A comprehensive search of selected databases (MEDLINE; EMBASE; CINAHL; Scopus; Cochrane; PSYCinfo; Web of Science) and grey literature was conducted in November 2021. Data was synthesised in a thematic presentation. Results: Three papers met the inclusion criteria, containing differences in design, types and dose of nature-based therapeutic interventions, outcome measures and target groups (n = 648). The papers showed tendencies toward a good treatment effect and positive economic effect in favour of NBT. Conclusions: Three different cohort studies have tried calculating the economic impact of NBT indicating a good effect of the NBT. The evidence on the economic benefits of NBT is still sparse though promising, bearing the limitations of the studies in mind. Economic evaluation of NBT is a new area needing more research, including high-quality research studies where the economic evaluation model is included/incorporated from the beginning of the study design. This will enhance the credibility and usefulness to policy makers and clinicians.

5 September 2024 in BMJ Open
Verified
Journal Article
Open access
PDF file
LKLine Planck Kongstad
Line Planck Kongstad
CØCecilie Krage Øverås
Cecilie Krage Øverås
CSChristian Skovsgaard
Christian Skovsgaard
LSLouise Fleng Sandal
Louise Fleng Sandal
JHJan Hartvigsen
Jan Hartvigsen
MSMette Jensen Stochkendahl
Mette Jensen Stochkendahl
Objectives This study aims to investigate the cost-effectiveness of individually tailored self-management support, delivered via the artificial intelligence-based selfBACK app, as an add-on to usual care for people with low back pain (LBP). Design Secondary health-economic analysis of the selfBACK randomised controlled trial (RCT) with a 9-month follow-up conducted from a Danish national healthcare perspective (primary scenario) and a societal perspective limited to long-term productivity in the form of long-term absenteeism (secondary scenario). Setting Primary care and an outpatient spine clinic in Denmark. Participants A subset of Danish participants in the selfBACK RCT, including 297 adults with LBP randomised to the intervention (n=148) or the control group (n=149). Interventions App-delivered evidence-based, individually tailored self-management support as an add-on to usual care compared with usual care alone among people with LBP. Outcome measures Costs of healthcare usage and productivity loss, quality-adjusted life-years (QALYs) based on the EuroQol-5L Dimension Questionnaire, meaningful changes in LBP-related disability measured by the Roland-Morris Disability Questionnaire (RMDQ) and the Pain Self-Efficacy Questionnaire (PSEQ), costs (healthcare and productivity loss measured in Euro) and incremental cost-effectiveness ratios (ICERs). Results The incremental costs were higher for the selfBACK intervention (mean difference €230 (95% CI −136 to 595)), where ICERs showed an increase in costs of €7336 per QALY gained in the intervention group, and €1302 and €1634 for an additional person with minimal important change on the PSEQ and RMDQ score, respectively. At a cost-effectiveness threshold value of €23250, the selfBACK intervention has a 98% probability of being cost-effective. Analysis of productivity loss was very sensitive, which creates uncertainty about the results from a societal perspective limited to long-term productivity. Conclusions From a healthcare perspective, the selfBACK intervention is likely to represent a cost-effective treatment for people with LBP. However, including productivity loss introduces uncertainty to the results. Trial registration number NCT03798288.

6 March 2025 in Health Economics
Verified
Journal Article
Open access
LKLine Planck Kongstad
Line Planck Kongstad
NDNicolai Damslund
Nicolai Damslund
Jens SøndergaardJens Søndergaard
Jens Søndergaard
GGGeir Godager
Geir Godager
KOKim Rose Olsen
Kim Rose Olsen
Mixed remuneration schemes with capitation and fee‐for‐service (FFS) payments hold financial incentives to add patients to the list and provide services to listed patients. However, as patients with complex needs tend to require longer consultations there is a risk of inequality in access if fees are not adjusted to patient characteristics. In this paper, we assess a natural experiment introducing additional capitation for GPs with a high share of complex patients (moderate scheme) and for GPs in certain geographical areas (intensive scheme). GPs are eligible if the complexity of their listed patients exceeds a threshold, but as the scheme is subject to a national budget constraint, some eligible general practitioners (GPs) are left without additional payment. For the most favored GPs, the reform distributed additional capitation at 8% of the total baseline income. We study the effects on the number of patients per GP and the number of services per patient, applying difference‐in‐difference (DiD) models. For both schemes (moderate and intensive), we find tendencies of reductions in the number of patients served and the level of service provision per patient. This also holds for complex patients indicating that the reform did not improve equity in access. The effect on income showed a 2.5% increase in the first follow‐up year but the effect became insignificant in the second year after the reform. We interpret this result as a sign that GPs trade income increases with leisure as suggested by the target income hypothesis.

15 October 2025 in BMJ Open
Verified
Journal Article
Open access
PDF file
SLSofus C. Larsen
Sofus C. Larsen
BHBerit Lilienthal Heitmann
Berit Lilienthal Heitmann
SWSarah Wane
Sarah Wane
SWSabrina Wielsøe
Sabrina Wielsøe
JLJane Lindschou
Jane Lindschou
FWFrans Boch Waldorff
Frans Boch Waldorff
Introduction Total diet replacements (TDRs) and weight loss medications (WLMs) have proven effective in producing substantial weight loss for individuals with obesity. Evidence is lacking on whether combining these treatments is effective and cost-effective in primary care for adults with obesity class I (body mass index (BMI) 30–34.9) or uncomplicated obesity class II or higher (BMI≥35 without obesity-related disease). Methods and analysis LightCARE is a 2-year 1:1 randomised, parallel-group, clinical superiority trial with blinded outcome assessment evaluating the benefits and harms of an intensive weight loss (IWL) intervention compared with usual care for adults with obesity in Denmark and the UK. The trial will include 400 participants aged 18–60 years with obesity class I or uncomplicated obesity class II or higher. The IWL programme aims to achieve and maintain a weight loss of ≥20% through a flexible and individualised combination of TDR, behavioural support, including physical activity and sleep guidance, and WLM if needed and will continue for 2 years. The control group will receive usual care offered in each country, typically consisting of brief behavioural support for weight loss. The primary outcome is body weight 2 years after randomisation. Secondary outcomes will include the proportion of participants achieving ≥20% weight loss, Short-Form-36 Mental Component Score, 4-m gait speed and Metabolic Syndrome Severity-Z score. Serious adverse events, the incidence of eating disorders and bone mineral density will be evaluated as safety outcomes. We will also examine the cost-effectiveness of the intervention, within the trial and in the longer term through modelling. We will conduct a process evaluation to inform any future implementation. Ethics and dissemination Ethical approval was granted in Denmark (December 2023, H-23051332) and the UK (August 2024, 24/SC/0210). Findings from the trial will be disseminated through peer-reviewed journals and scientific conferences. Trial registration number NCT06321432.

30 March 2026 in Health Economics Review
Verified
Journal Article
Open access
PDF file
LPLouise Schubert Paaske
Louise Schubert Paaske
NDNicolai Simonsen Damslund
Nicolai Simonsen Damslund
IMIda Elisabeth Huitfeldt Madsen
Ida Elisabeth Huitfeldt Madsen
SJSofie Jaspers
Sofie Jaspers
LKLine Planck Kongstad
Line Planck Kongstad
Healthcare workers are frequently exposed to high emotional demands through encounters with patient suffering, death, worries, and aggressive reactions. Su

8 September 2025 in JMIR Research Protocols
Verified
Journal Article
Open access
KBKirubakaran Balasubramaniam
Kirubakaran Balasubramaniam
LSLine Maria Simonsen
Line Maria Simonsen
LKLine Planck Kongstad
Line Planck Kongstad
TTTrine Thilsing
Trine Thilsing
SWSonja Wehberg
Sonja Wehberg
Jens SøndergaardJens Søndergaard
Jens Søndergaard
Background: Acute respiratory infections (ARIs) are frequent reasons for medical consultations in general practice and can lead to unnecessary recontacts. Introducing new point-of-care (POC) polymerase chain reaction (PCR) diagnostic equipment may offer an attractive and efficient way of providing a more precise and exact microbial diagnosis. Successful uptake of POC PCR equipment could potentially lead to a reduction in recontacts with benefits for both staff and patients. However, introducing new diagnostic technology is a complex intervention and several contextual factors may impact the implementation. Objective: This study aims to evaluate the effect of POC PCR test availability in general practice on the subsequent (1) number of recontacts to the general practitioner (GP) for patients with symptoms of ARIs (primary outcome) and (2) hospital admissions, deaths, antibiotic prescriptions, health-related quality of life, GP and patient satisfaction, costs, cost-effectiveness, and contextual facilitators and barriers conditioning the implementation process (secondary outcomes). Methods: This study is a cluster-randomized, crossover, nonblinded superiority trial with a 1:1 allocation ratio between usual care (control) and POC PCR test availability (intervention). Questionnaire data are collected at day 0, 7, 14, and 28 after the initial contact (health-related quality of life, absenteeism and presentism among patients, and patient satisfaction) and after finalization of the study period (GP satisfaction). Data on recontacts, hospital admissions, redeemed antibiotic prescriptions, costs, and deaths will be retrieved from the Danish national registries. The implementation process will be evaluated based on data from interviews with users of POC PCR tests (i.e., GPs, staff, and patients) and from observations in the clinics in line with Medical Research Council guidelines. Results: As per the randomized crossover design carried out during September 2023 to March 2024 investigating a sample of 100 GP clinics, we expect to obtain an in-depth and multifaceted understanding of the effects of the availability of the POC PCR test equipment in general practice. Conclusions: This study will provide valuable information about the diagnostic conditions and possibilities in general practice and provide insights into the organization of primary health care. Trial Registration: ClinicalTrials.gov NCT06120153; https://clinicaltrials.gov/study/NCT06120153 International Registered Report Identifier (IRRID): DERR1-10.2196/72842